KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.

In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to ixazomib. In this study we examined factors respo...

Full description

Bibliographic Details
Main Authors: Nibedita Chattopadhyay, Allison J Berger, Erik Koenig, Bret Bannerman, James Garnsey, Hugues Bernard, Paul Hales, Angel Maldonado Lopez, Yu Yang, Jill Donelan, Kristen Jordan, Stephen Tirrell, Bradley Stringer, Cindy Xia, Greg Hather, Katherine Galvin, Mark Manfredi, Nelson Rhodes, Ben Amidon
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4692403?pdf=render

Internet

http://europepmc.org/articles/PMC4692403?pdf=render

Similar Items